• +1-646-491-9876
    • +91-20-67278686

    Search

    Serine/Threonine Protein Kinase Pim 3-Pipeline Review H1 2017

    Serine/Threonine Protein Kinase Pim 3-Pipeline Review H1 2017

    • Report Code ID: RW0001834340
    • Category Pharmaceuticals
    • No. of Pages 34
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'SerineThreonine Protein Kinase Pim 3 - Pipeline Review, H1 2017'; Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Serine/threonine-protein kinase Pim-3 is an enzyme encoded by the PIM3. It prevents apoptosis. It contribute to tumorigenesis through the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L) , by regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity.

    The report 'SerineThreonine Protein Kinase Pim 3 - Pipeline Review, H1 2017' outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Immunology and Infectious Disease which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Chronic Lymphocytic Leukemia (CLL) , Pancreatic Cancer, Bladder Cancer, Hematological Tumor, Influenza virus A Infections, Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Carcinoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Viral Infections.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)
    - The report reviews Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Overview
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    Incyte Corp
    Inflection Biosciences Ltd
    Jasco Pharmaceuticals LLC
    Novartis AG
    Onconova Therapeutics Inc
    Tolero Pharmaceuticals Inc
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Drug Profiles
    IBL-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INCB-53914 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LGB-321 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ON-108110 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PIM-447 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Pim Kinase for Pancreatic Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    T-18 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-3654 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Dormant Products
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Discontinued Products
    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Product Development Milestones
    Featured News & Press Releases
    Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma
    Apr 01, 2013: Jasco Pharma To Present Data On PIM Inhibitor Program At AACR Annual Meeting 2013
    Mar 31, 2011: Jasco Pharma To Present Data On Preclinical PIM Inhibitor Program At AACR Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Incyte Corp, H1 2017
    Pipeline by Inflection Biosciences Ltd, H1 2017
    Pipeline by Jasco Pharmaceuticals LLC, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by Onconova Therapeutics Inc, H1 2017
    Pipeline by Tolero Pharmaceuticals Inc, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Incyte Corp
    Inflection Biosciences Ltd
    Jasco Pharmaceuticals LLC
    Novartis AG
    Onconova Therapeutics Inc
    Tolero Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//serine-threonine-protein-kinase-pim-3-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//serine-threonine-protein-kinase-pim-3-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//serine-threonine-protein-kinase-pim-3-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments